KangaBio present preclinical data of IL-12 prodrug KGX101 at AACR 2024
Time：2024-4-10

At the American Association for Cancer Research (AACR) Annual Meeting in San Diego, USA, on April 5-10, 2024, kangabio presented preclinical data on a new generation of cytokine IL-12 prodrug (pipeline code: KGX101).

KGX101 is a prodrug molecule of the cytokine interleukin-12 (IL-12), which effectively prolongs its serum half-life by fusing with the antibody Fc region. Simultaneously, KGX101 is a prodrug, masked by receptors via fusion with tumor-specific protease cleavage linkers, thus enhancing the enrichment of active drug in the tumor region and reducing the systemic toxicity of cytokine. Once the linker is cleaved by specific metalloproteinases in the tumor microenvironment, KGX101 can effectively stimulate immune cells in the tumor, remodeling the tumor microenvironment. Preclinical studies have shown that KGX101 exhibits excellent anti-tumor activity, as well as favorable pharmacokinetics and tolerability. The Investigational New Drug (IND) application for KGX101 has been formally approved by the U.S. Food and Drug Administration (FDA). The company will simultaneously conduct Phase I clinical trials of KGX101 monotherapy or in combination with PD-L1 inhibitor for the treatment of advanced solid tumors in the United States and Australia. Several sites in Australia have already initiated the trials, with the first patient dosed in Q4 2023.

参考文献

1. Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., Vom Berg, J., Kulig, P., & Becher, B. (2015). New insights into IL-12-mediated tumor suppression. In Cell Death and Differentiation (Vol. 22, Issue 2, pp. 237–246). Nature Publishing Group. https://doi.org/10.1038/cdd.2014.134

2. Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020). Localized Interleukin-12 for Cancer Immunotherapy. In Frontiers in Immunology (Vol. 11). Frontiers Media S.A. https://doi.org/10.3389/fimmu.2020.575597

3. Xue, D., Moon, B., Liao, J., Guo, J., Zou, Z., Han, Y., Cao, S., Wang, Y., Fu, Y.-X., & Peng, H. (2022). A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. In Sci. Immunol (Vol. 7). https://www.science.org